Abstract: Example embodiments of the present disclosure provide for an example method. The example method includes generating an initial user interface including a content assistant component. The example method include obtaining user input data. The example method includes processing, by a machine learned model interfacing with the content assistant component, the data indicative of the input received from the user. The method includes obtaining output data, from the machine learned model interfacing with the content assistant component, indicative of one or more content item components. The method includes transmitting data which causes the content item components to be provided for display via an updated user interface. The method includes obtaining data indicative of user selection of approval of the content item components. The method includes generating, in response to obtaining the data indicative of the user selection of the approval of the content item components, content items.

Abstract: The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject by evaluating the subject's expression levels of specific biomarkers or angiogenic an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment factors.

Abstract: The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin/activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.

Abstract: The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin/activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.

Abstract: Methods, systems, and apparatus, including computer-readable storage media for generating model-generated digital content based on prompts and other inputs. The prompts may be, for example, inputs for modifying digital content associated with an existing campaign. The prompts may include national language input. The natural language prompts may include, for example, a theme, information related to an upcoming event, the topic of the campaign, or the like. The other inputs may also include information associated with the campaign creator's style. The information associated with the campaign creator's style may be in the form of embeddings. A system implementing the methods described herein can generate the digital content for the modified campaign based on the received inputs received from the campaign. The generated digital content may be in the form of text, image, or the like.

Abstract: This invention disclosure describes novel polypeptide antagonists capable of neutralizing multiple members of TGF-? family in a selective manner. Specifically, the multispecific polypeptide antagonists disclosed herein comprise at least one Activin-binding domain and at least one TGF-?-binding domain and therefore, are capable of neutralizing TGF-? and Activin as well as Activin-related ligands in parallel. Moreover, this invention disclosure also discloses bifunctional multispecific polypeptide antagonists designed to inhibit Activin, TGF-? and T-Cell immune checkpoint (i.e., PD1, PDL1 or CTLA4) in a simultaneous manner. Specifically, the bifunctional multispecific antagonists disclosed herein comprise at least one Activin-binding domain, at least one TGF-?-binding domain and at least one PD1-, PDL1- or CTLA4-binding domain.

Abstract: This disclosure related to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.

Abstract: The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin/activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.

Abstract: Example embodiments of the present disclosure provide for an example method. The example method includes generating an initial user interface including a content assistant component. The example method include obtaining user input data. The example method includes processing, by a machine learned model interfacing with the content assistant component, the data indicative of the input received from the user. The method includes obtaining output data, from the machine learned model interfacing with the content assistant component, indicative of one or more content item components. The method includes transmitting data which causes the content item components to be provided for display via an updated user interface. The method includes obtaining data indicative of user selection of approval of the content item components. The method includes generating, in response to obtaining the data indicative of the user selection of the approval of the content item components, content items.

Abstract: Example embodiments of the present disclosure provide for an example method. The example method includes generating an initial user interface including a content assistant component. The example method include obtaining user input data. The example method includes processing, by a machine learned model interfacing with the content assistant component, the data indicative of the input received from the user. The method includes obtaining output data, from the machine learned model interfacing with the content assistant component, indicative of one or more content item components. The method includes transmitting data which causes the content item components to be provided for display via an updated user interface. The method includes obtaining data indicative of user selection of approval of the content item components. The method includes generating, in response to obtaining the data indicative of the user selection of the approval of the content item components, content items.

Abstract: Example embodiments of the present disclosure provide for an example method. The example method includes generating an initial user interface including a content assistant component. The example method include obtaining user input data. The example method includes processing, by a machine learned model interfacing with the content assistant component, the data indicative of the input received from the user. The method includes obtaining output data, from the machine learned model interfacing with the content assistant component, indicative of one or more content item components. The method includes transmitting data which causes the content item components to be provided for display via an updated user interface. The method includes obtaining data indicative of user selection of approval of the content item components. The method includes generating, in response to obtaining the data indicative of the user selection of the approval of the content item components, content items.

Abstract: Example embodiments of the present disclosure provide for an example method that includes obtaining via a conversational campaign assistant interface, by a custom language model, natural language input. The method includes generating, by the custom language model, an output comprising a predicted user intent. The method includes determining actions to perform and determining a natural language response. The method includes transmitting, to an action component, the action data structure comprising executable instructions that cause the action component to automatically perform operations associated with completing the action. The method includes transmitting to the conversation campaign assistant interface, the response data structure comprising the natural language response to be provided for display to a user via the conversational campaign assistant interface.

Abstract: The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin/activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.

Abstract: This invention disclosure provides novel bifunctional antagonistic polypeptides comprising at least one TNF-? binding domain and at least one Activin-binding domain, which are highly capable of sequestering TNF-? and Activin or Activin-related ligand in parallel. Also provided are pharmaceutical compositions of such bifunctional polypeptide antagonists and their uses to treat various complex disease conditions, whose pathogenesis involve the activation of both TNF-?-mediated NF-?B signaling pathway and Activin-mediated Smad2/3 signaling pathway.

Abstract: This invention disclosure provides novel bifunctional antagonistic polypeptides comprising at least one TNF-? binding domain and at least one TGF-? binding domain, which are highly capable of sequestering TNF-? and TGF-? in parallel. Also provided are pharmaceutical compositions of such bifunctional polypeptide antagonists and their uses to treat various complex disease conditions, whose pathogenesis involve the activation of both TNF-?-mediated NF-?B signaling pathway and TGF-?-mediated Smad2/3 signaling pathway.

Abstract: This invention disclosure provides novel bifunctional molecules comprising at least one RANKL binding molecule and at least one Activin or TGF-? binding molecule, which are capable of sequestering RANKL and Activin or TGF-? in parallel. Also provided are pharmaceutical compositions of such bifunctional antagonist molecules and their therapeutic uses to treat various bone disorders whose pathogenesis involves the activation of both RANKL-NF?B and Activin/TGF?-Smad2/3 signaling pathways, such as bone metastasis, bone loss in cancer, bone fragility in neuromuscular diseases, osteogenesis imperfecta, fracture, osteopenia and osteoporosis.

Abstract: The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject by evaluating the subject's expression levels of specific biomarkers or angiogenic an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment factors.

Abstract: The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject by evaluating the subject's expression levels of specific biomarkers or angiogenic an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment factors.

Abstract: The disclosure provides compositions and methods relating to or derived from anti-activin A binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin A antibodies that bind human activin A, activin A-binding fragments and derivatives of such antibodies, and activin A-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having activin A-related disorders or conditions including cachexia related to gonadal cancer, other cancers, rheumatoid arthritis, and other diseases.

Abstract: The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin/activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.